A spring 2014 course from Ohio State University will emphasize Duchenne muscular dystrophy mechanisms, research, and clinical and social aspects
posted on January 8, 2014 - 12:09pm
A course on Duchenne muscular dystrophy (DMD), geared toward graduate and upper-division undergraduate students and held at Ohio State University College of Medicine and Nationwide Children's Hospital in Columbus, is open to the public, without charge, via real-time streaming and podcasts.
Biologist Denis Guttridge discusses his team's work developing an NF-kappa B blocker as a potential treatment for Duchenne MD
posted on December 14, 2011 - 3:56pm
A December 2011 podcast from Nationwide Children's Hospital in Columbus, Ohio, explores how an inhibitor of a protein called NF-kappa B has been beneficial in a mouse model of Duchenne muscular dystrophy (DMD) and is now being developed as a potential DMD treatment.
The podcast is part of a Nationwide Children's series called "This Month in Muscular Dystrophy."
The underlying cause of Duchenne muscular dystrophy (DMD) can be any of a large number of mutations in the gene for the dystrophin protein. One strategy now being tested for overcoming this problem is gene therapy, the insertion of new dystrophin genes. Another is the transplantation of cells that give rise to muscle.